IM Cannabis Corp.
IM Cannabis Corp. is a medical cannabis company with operations in Israel and Germany. The company imports, distributes, and retails medical cannabis products through pharmacies, trade houses, and online platforms, and it also operates branded cannabis portfolios in Europe.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDried flower products sold to medical patients through pharmacies and distributors.
Full-spectrum extracts and related medical cannabis formulations.
Imported cannabis supplied to pharmacies and trade houses in core markets.
Patient-facing dispensing and digital ordering platforms in Israel.
IMC-branded, mid-market, value, and premium cannabis products.
Customers
IM Cannabis primarily serves medical cannabis patients, with products reaching them through pharmacies, trade houses, and company-operated retail channels. In Germany, the company sells through pharmacies serving medical patients, while in Israel it supplies patients via licensed pharmacies and its own retail and online platforms. The buyer set is therefore mostly medical end users, with pharmacies and distributors acting as the key channel customers.
Buy imported and locally supplied medical cannabis through licensed pharmacies and IMC retail channels for prescribed treatment.
Receive cannabis products through pharmacies supplied by IMC's German distribution business.
Purchase cannabis products for prescription fulfillment and patient dispensing.
Buy product inventory and distribution services that link supply to the patient channel.
Order medical cannabis through IMC-operated digital platforms in Israel for convenience and control.
Strategy
IM Cannabis is focused on building a branded medical-cannabis platform across Israel and Germany, using distribution, retail, and product branding as its main commercial levers. The company’s strategy also emphasizes supply reliability, portfolio expansion across price tiers, and leveraging patient and product data to support market positioning. It continues to evaluate opportunities to extend into additional technology-driven sectors, but its present operating model remains centered on medical cannabis.
A broader price ladder helps reach more patients and improve shelf presence across pharmacies.
Medical cannabis demand depends on consistent product availability and regulatory-compliant sourcing.
Pharmacies are the main route to medical patients in both core markets.
Historical usage data and credibility can support product development and repeat demand.
Geography
IM Cannabis is centered on Israel and Germany, which together represent the company’s core operating footprint and revenue base. The business also uses Canadian sourcing and cultivation relationships to support supply into its patient markets, but commercial activity is concentrated in Europe and Israel. Geography matters because each market has distinct medical-cannabis regulation, licensing, and distribution requirements that shape how the company sells and operates.
Risks
IM Cannabis is exposed to regulatory, licensing, and execution risks because its business depends on medical-cannabis approvals, import permissions, and pharmacy distribution in tightly controlled markets. It also faces supply-chain and quality-control risk from cross-border sourcing, plus valuation and impairment risk tied to goodwill and other judgmental balance-sheet items. Industry competition, pricing pressure, and changing patient demand can affect sell-through across both Israel and Germany.
- Regulatory and licensing dependencyImpact: HighLikelihood: High
The company operates only through medical-cannabis permits, import rights, and pharmacy distribution approvals.
Exposure: Israel and Germany
- Supply-chain and sourcing disruptionImpact: HighLikelihood: Medium
The model relies on Canadian suppliers, imports, and third-party cultivation to maintain product availability.
Exposure: Cross-border cannabis supply
- Goodwill impairmentImpact: HighLikelihood: Medium
The group tests goodwill against estimated future cash flows from Israel, Canada, and Germany cash-generating units.
Exposure: Balance sheet goodwill
- Competitive pricing pressureImpact: MediumLikelihood: High
Medical cannabis markets feature branded and generic substitutes, which can compress demand for higher-priced products.
Exposure: Germany and Israel
Accounting
Judgemental itemsRecoverable value is based on cash-flow projections for Israel, Canada, and Germany units.
Impact: Can create large non-cash charges if forecasts weaken
Level 3 valuations rely on discounted future cash flows and risk assumptions.
Impact: Changes estimates and reported asset values
Management must estimate outcomes and potential settlement costs.
Impact: Can affect expenses and liabilities
The group operates in CAD, USD, NIS, and EUR-related markets.
Impact: Can move reported earnings and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Intercure Ltd.
INCR · Pharmaceutical Preparations
Aurora Cannabis Inc
ACB · Medicinal Chemicals & Botanical Products
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Cannapharmarx, Inc.
CPMD · Pharmaceutical Preparations
Ispire Technology Inc.
ISPR · Cigarettes
InMed Pharmaceuticals Inc.
INM · Pharmaceutical Preparations
Last updated: 28/09/2026